• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Precipio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    6/15/26 4:01:11 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $PRPO alert in real time by email
    false 0001043961 0001043961 2026-06-15 2026-06-15 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D. C. 20549

      

    FORM 8-K

     

    CURRENT REPORT
    PURSUANT TO SECTION 13 OR 15(d) OF THE
    SECURITIES EXCHANGE ACT OF 1934

     

    Date of report (Date of earliest event reported): June 15, 2026

     

    PRECIPIO, INC.
    (Exact Name of Registrant as Specified in Its Charter)

     

    Delaware   001-36439   91-1789357

    (State of Incorporation)

      (Commission File Number)   (I.R.S. Employer Identification No.)

     

    4 Science Park, New Haven, CT 06511

    (Address of principal executive offices) (Zip Code)

     

    (203) 787-7888

    (Registrant's telephone number, including area code)

     

    Not Applicable
    (Former name, former address and former fiscal year, if changed since last report date)

      

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

     

    ¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

     

    ¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

     

    ¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:
    Title of each class Ticker symbol(s) Name of each exchange on which
    registered
    Common Stock, $0.01 par value per share PRPO Nasdaq Capital Market

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.

     

    Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

     

     

     

     

     

     

    Item 5.07Submission of Matters to a Vote of Security Holders.

     

    On June 15, 2026, Precipio, Inc. (the “Company”) convened its Annual Meeting of stockholders for the purpose of holding a stockholder vote (the “Annual Meeting”). At the Annual Meeting, the stockholders of the Company voted:

     

    1.To elect Richard Sandberg, Christina Valauri, and Jeffrey Cossman, M.D. as Class II directors for terms to expire in 2029 (“Proposal One”);

     

    2.To ratify the appointment of CBIZ CPAs, P.C. (“CBIZ”) as our independent registered public accounting firm for the year ending December 31, 2026 (“Proposal Two”).

      

    The proposals are described in detail in the Company’s definitive proxy statement for the Annual Meeting filed with the Securities and Exchange Commission on April 28, 2026 (the “Proxy Statement”).

     

    The number of shares of common stock entitled to vote at the Annual Meeting was 1,784,830. The number of shares of common stock present or represented by valid proxy at the Annual Meeting was 1,063,293, representing 59.57% of the total number of outstanding shares of the Company. Proposals One and Proposal Two submitted to a vote of the Company’s stockholders at the Annual Meeting were approved.

     

    The votes cast with respect to each matter voted upon are set forth below.

     

    Proposal One: To elect Richard Sandberg, Christina Valauri, and Jeffrey Cossman, M.D. as Class II directors for terms to expire in 2029, as set forth in the Proxy Statement. The results of the election were as follows:

     

      Votes For Votes Against Withheld Brokers Non-Votes
    Total Shares Voted 551,150 0 1,058 511,085

      

    Richard Sandberg

      Votes For Votes Against Withheld  
    Total Shares 535,205 0 17,003  

      

    Christina Valauri

      Votes For Votes Against Withheld  
    Total Shares 544,692 0 7,516  

      

    Jeffrey Cossman, M.D

      Votes For Votes Against Withheld  
    Total Shares 534,990 0 17,218  

      

    Proposal Two: To ratify the appointment of CBIZ CPAs, P.C. (“CBIZ”) as our independent registered public accounting firm for the year ending December 31, 2026, as set forth in the Proxy Statement. The results of the election were as follows:

      

      Votes For Votes Against Abstain  
    Total Shares Voted 1,051,812 10,583 898  

      

    No other matters were submitted to or voted on by the Company’s shareholders at the Annual Meeting.

     

     

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     

      PRECIPIO, INC.
       
      By: /s/ Ilan Danieli
      Name: Ilan Danieli
      Title: Chief Executive Officer

     

    Date: June 15, 2026

     

     

    Get the next $PRPO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRPO

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PRPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Sandberg Richard A sold $22,517 worth of shares (900 units at $25.02) (SEC Form 4)

    4 - Precipio, Inc. (0001043961) (Issuer)

    5/26/26 4:00:15 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Director Sandberg Richard A sold $77,784 worth of shares (3,134 units at $24.82), decreasing direct ownership by 20% to 8,142 units (SEC Form 4)

    4 - Precipio, Inc. (0001043961) (Issuer)

    5/21/26 4:00:21 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 4 filed by Valauri Christina Rizopoulos

    4 - Precipio, Inc. (0001043961) (Issuer)

    4/17/26 5:01:48 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $PRPO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $PRPO
    SEC Filings

    View All

    Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting

    NEW HAVEN, Conn., June 12, 2026 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately. Votes must be received by 11:59 p.m., Eastern Time, on June 14, 2026, to be voted at the Annual Meeting. In order to ensure that there is a quorum required for the shareholders' meeting that is scheduled to take place tomorrow, June 15, 2026, at 10 a.m. Eastern Time. At the time of this press release, approximately 42% of shares have been voted. For the company to hold the shareholder meeting, a minimum of 50% of shares must be voted. If the Company does not receive suf

    6/12/26 1:00:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio to Present at the Planet MicroCap Las Vegas

    NEW HAVEN, Conn., June 11, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that it will be presenting at the Planet MicroCap Las Vegas 2026 on Wednesday, June 17, 2026, at 9:00 AM (Local Time, 12:00pm EST) at the Bellagio Resort & Hotel. Ilan Danieli, CEO and Zaki Sabet, COO of Precipio will be hosting the presentation and answering questions at the conclusion. "We're excited to participate in the Planet MicroCap conference and are looking forward to meeting with many of our existing, as well as new potential shareholders," said Ilan Danieli, CEO. "As a profitable company that is looking to raise awareness rather than raise capital, th

    6/11/26 5:00:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Announces Q1 2026 Financial Results

    NEW HAVEN, Conn., May 14, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces financial results for the first quarter ended March 31, 2026. Below are some of the key financial performance metrics for the Company. Please see the Company's Form 10-Q which was filed today for additional details. Revenue – $6.71M (vs. $6.69M in Q4-2025; $4.93M in Q1-2025). This was comprised of $6.05M in pathology revenue (up from $5.9M in Q4) and $0.66M in product revenue (down from $0.74M in Q4). The product revenue decline is temporary, and was largely driven by delayed shipment to one of the Company's largest product customers, shifting revenue recogn

    5/14/26 5:00:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Chief Operating Officer Sabet Ahmed Zaki bought $468 worth of shares (20 units at $23.40), increasing direct ownership by 2% to 1,015 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:22:27 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Chief Operating Officer Sabet Ahmed Zaki bought $488 worth of shares (25 units at $19.50), increasing direct ownership by 3% to 995 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:21:46 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Amendment: Chief Operating Officer Sabet Ahmed Zaki bought $505 worth of shares (31 units at $16.30), increasing direct ownership by 3% to 970 units (SEC Form 4)

    4/A - Precipio, Inc. (0001043961) (Issuer)

    1/20/26 4:19:49 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

    8-K - Precipio, Inc. (0001043961) (Filer)

    6/15/26 4:01:11 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    SEC Form 10-Q filed by Precipio Inc.

    10-Q - Precipio, Inc. (0001043961) (Filer)

    5/14/26 4:16:28 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Precipio, Inc. (0001043961) (Filer)

    5/6/26 5:15:42 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Financials

    Live finance-specific insights

    View All

    Precipio is requesting Shareholders/Brokers vote today to avoid costly adjournment and rescheduling of Annual Shareholders Meeting

    NEW HAVEN, Conn., June 12, 2026 (GLOBE NEWSWIRE) -- Management of specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO) is requesting that shareholders instruct their brokers to vote their shares immediately. Votes must be received by 11:59 p.m., Eastern Time, on June 14, 2026, to be voted at the Annual Meeting. In order to ensure that there is a quorum required for the shareholders' meeting that is scheduled to take place tomorrow, June 15, 2026, at 10 a.m. Eastern Time. At the time of this press release, approximately 42% of shares have been voted. For the company to hold the shareholder meeting, a minimum of 50% of shares must be voted. If the Company does not receive suf

    6/12/26 1:00:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio to Present at the Planet MicroCap Las Vegas

    NEW HAVEN, Conn., June 11, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces that it will be presenting at the Planet MicroCap Las Vegas 2026 on Wednesday, June 17, 2026, at 9:00 AM (Local Time, 12:00pm EST) at the Bellagio Resort & Hotel. Ilan Danieli, CEO and Zaki Sabet, COO of Precipio will be hosting the presentation and answering questions at the conclusion. "We're excited to participate in the Planet MicroCap conference and are looking forward to meeting with many of our existing, as well as new potential shareholders," said Ilan Danieli, CEO. "As a profitable company that is looking to raise awareness rather than raise capital, th

    6/11/26 5:00:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Precipio Announces Q1 2026 Financial Results

    NEW HAVEN, Conn., May 14, 2026 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), announces financial results for the first quarter ended March 31, 2026. Below are some of the key financial performance metrics for the Company. Please see the Company's Form 10-Q which was filed today for additional details. Revenue – $6.71M (vs. $6.69M in Q4-2025; $4.93M in Q1-2025). This was comprised of $6.05M in pathology revenue (up from $5.9M in Q4) and $0.66M in product revenue (down from $0.74M in Q4). The product revenue decline is temporary, and was largely driven by delayed shipment to one of the Company's largest product customers, shifting revenue recogn

    5/14/26 5:00:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Leadership Updates

    Live Leadership Updates

    View All

    Precipio Inc. Announces the Resignation of its Chief Financial Officer and Appointment of Interim CFO

    NEW HAVEN, Conn., March 21, 2022 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ:PRPO), today announced that Mr. Carl Iberger, Precipio's CFO for the past five years, is resigning as the Chief Financial Officer effective as of today, March 21st, 2022. Mr. Iberger wishes to spend more time with his family and therefore has made the decision to step down from his role as CFO. Matt Gage, who currently serves as Director of Financial Reporting and Analysis has been promoted to Interim Chief Financial Officer of the Company effective immediately. Mr. Gage joined Precipio following its acquisition of Transgenomic in July of 2017. He has worked closely with Mr. Ib

    3/21/22 5:00:00 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    89bio Announces Appointment of Kathy LaPorte to its Board of Directors

    SAN FRANCISCO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (NASDAQ:ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced the appointment of Kathy LaPorte to its Board of Directors, effective immediately. Ms. LaPorte brings deep expertise and valuable experience in the industry to the Company. "It is a pleasure to welcome Kathy, an esteemed industry leader, to our Board of Directors," said Rohan Palekar, Chief Executive Officer of 89bio. "Kathy has a strong track record for enhancing operational capabilities to drive growth. Her extensive experien

    11/3/21 8:00:00 AM ET
    $BOLT
    $ETNB
    $PRPO
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    Mr. Richard Sandberg is appointed Chairman of Precipio’s Board of Directors

    NEW HAVEN, Conn., March 03, 2021 (GLOBE NEWSWIRE) -- Specialty cancer diagnostics company Precipio, Inc. (NASDAQ: PRPO) announces the appointment of Mr. Richard Sandberg as Chairman of the Board of Directors. Dr. Douglas Fisher will step down as Chairman and maintain his role as a Director on the company’s board. Mr. Sandberg has been involved with Precipio since its inception and has acted in various advisory roles. in 2019 he joined the company’s Board of Directors and has been a significant contributor to helping the company formulate strategy and execute on its plans. Mr Sandberg is a seasoned diagnostics executive with a substantial track record in the field of diagnostics. As the f

    3/3/21 11:00:00 AM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $PRPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Precipio Inc.

    SC 13G - Precipio, Inc. (0001043961) (Subject)

    8/2/24 2:15:53 PM ET
    $PRPO
    Biotechnology: Laboratory Analytical Instruments
    Industrials